TrialJournal of the European Academy of Dermatology and Venereology : JEADV2022

Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial.

C Ryan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.